References
- Kaltenboeck A, Bach P. Value-based pricing for drugs: theme and variations. JAMA. 2018;319:2165–2166.
- Mailankody S, Bach PB. Money-back guarantees for expensive drugs: wolf’s clothing but a sheep underneath. Ann Intern Med. 2018;168:888–889.
- Garrison LP, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16:703–719.
- Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336:251–254.
- Drummond M, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. New York (NY): Oxford University Press; 2015.
- Fenwick E, Marshall DA, Levy AR, et al. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res. 2006;6:52.
- U.S. Bureau of Labor Statistics. Prescription drugs in U.S. city average, all urban consumers, seasonally adjusted. [accessed December 2019]. Available from: https://data.bls.gov/timeseries/CUSR0000SEMF01?output_view=pct_3mths
- Campbell MK, Torgerson DJ. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. QJM. 1999;92:177–182.
- Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York (NY): Oxford University Press; 2011.
- Soria J, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–125.
- RedBook Online [subscription database online]. Greenwood Village (CO): Truven Health Analytics. [accessed December 2019, updated periodically]. Available from: http://micromedex.com/products/product-suites/clinical-knowledge/redbook
- Skinner KE, Fernandes AW, Walker MS, et al. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study. J Med Econ. 2018;21:192–200.
- Aguiar J, Pedro N, Haaland B, et al. cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4:1080–1084.
- Ting J, Tien Ho P, Xiang P, et al. Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non-small-cell lung cancer in the united states. Value Health. 2015;18:774–782.
- Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8:204–215.
- Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.
- Burkholder R, Dougherty JS, Neves LA. ISPOR’s initiative on US value assessment frameworks: an industry perspective. Value Health. 2018; 21:173–175.
- Griffith D. Four types of price variation. Laramie (WY); March 2013. [accessed December 2019]. Available from: http://www.uwagec.org/rightrisk/presentations/2013_03_26_DGriffithMarketing/1_Introduction/1_FourTypesPriceVariation.pdf
- Bodoh-Creed A, Boehnke J, Hickman B. Using machine learning to predict price dispersion. Scholars at Harvard. [accessed December 2019]. Available from: https://scholar.harvard.edu/files/boehnke/files/bcbh_machine_learning_price_dispersion.pdf
- Lakdawalla DN, Doshi JA, Garrison LP, Jr, et al. Defining elements of value in health care-a health economics approach: an ISPOR special task force report [3]. Value Health. 2018;21:131–139.
- Office of the Legislative Counsel. Patient protection and affordable care act, 42 U.S.C § 18001 2010. USA; 2010 [accessed December 2019]. Available from: https://www.hhs.gov/sites/default/files/ppacacon.pdf
- Bertranou E, Bodnar C, Dansk V, et al. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. J Med Econ. 2018;21:113–121.
- Weintraub WS, Cohen JD. The limits of cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2009;2:55–58.
- Alkhatib NS, McBride A, Bhattacharjee S, et al. Pricing methods in outcome-based contracting-δ5: risk of efficacy failure-based pricing. J Med Econ. 2020;23(11):1246–1255.